Opioid-specific brain connectivity dynamics distinguish analgesia from secondary effects: Studies in male mice

阿片类药物特异性脑连接动力学区分镇痛作用与继发效应:雄性小鼠研究

阅读:1

Abstract

The µ-opioid receptor (MOP) is a critical pharmaceutical target that mediates both the therapeutic benefits and adverse effects of opioid drugs. However, the large-scale neural circuit dynamics underlying key opioid effects, such as analgesia and respiratory depression, remain poorly understood, hindering the development of safer analgesics. Here, we present a multimodal experimental framework that integrates functional ultrasound imaging through the intact skull with behavioral and molecular analyses to investigate opioid-induced large-scale functional responses and their physiological relevance in awake, behaving male mice. Administration of major opioids-morphine, fentanyl, methadone, and buprenorphine-elicited robust, dose- and time-dependent reorganization of functional brain connectivity (FC) patterns, with magnitude scaling according to MOP agonist efficacy. This opioid-specific functional fingerprint is marked by decreased FC between the somatosensory cortex and hippocampal/thalamic regions and increased bilateral FC within the somatosensory cortex. Notably, this fingerprint was attenuated following tolerance induction and abolished by pharmacological or genetic MOP inactivation. Through power Doppler spectral analysis and lagged correlation measurements, we show that morphine perturbs temporal FC dynamics and the propagation of brain-wide oscillatory activity, disrupting critical-state dynamics. Importantly, we identify a dissociation between fast, transient processes-such as cerebral blood volume changes, locomotion, and respiratory depression-and slower processes driving FC reorganization, analgesia, and sustained MOP activation. This study provides mechanistic insights into opioid-induced network reorganization, establishes FC alterations as a reliable biomarker of opioid efficacy, and offers a framework for advancing the development of analgesic compounds with improved therapeutic windows and reduced side effects.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。